1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Stonepine Capital Management, LLC Buys Ligand Pharmaceuticals Inc, Stemline Therapeutics Inc, Cidara Therapeutics Inc, Sells Oxford Immunotec Global PLC, Adamas Pharmaceuticals Inc, Affimed NV

Investment company Stonepine Capital Management, LLC (Current Portfolio) buys Ligand Pharmaceuticals Inc, Stemline Therapeutics Inc, Cidara Therapeutics Inc, Catalyst Biosciences Inc, BioDelivery Sciences International Inc, sells Oxford Immunotec Global PLC, Adamas Pharmaceuticals Inc, Affimed NV, Novelion Therapeutics Inc, Aptevo Therapeutics Inc during the 3-months ended 2020Q1, according to the most recent filings of the investment company, Stonepine Capital Management, LLC. As of 2020Q1, Stonepine Capital Management, LLC owns 26 stocks with a total value of $92 million. These are the details of the buys and sells.

For the details of Stonepine Capital Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/stonepine+capital+management%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Stonepine Capital Management, LLC
  1. Ligand Pharmaceuticals Inc (LGND) - 160,919 shares, 12.77% of the total portfolio. New Position
  2. IVERIC bio Inc (ISEE) - 2,583,786 shares, 9.70% of the total portfolio. Shares reduced by 13.87%
  3. CTI BioPharma Corp (CTIC) - 6,430,637 shares, 6.45% of the total portfolio. Shares added by 71.26%
  4. Amarin Corp PLC (AMRN) - 1,313,100 shares, 5.73% of the total portfolio. Shares reduced by 15.35%
  5. Affimed NV (AFMD) - 3,000,000 shares, 5.17% of the total portfolio. Shares reduced by 25.19%
New Purchase: Ligand Pharmaceuticals Inc (LGND)

Stonepine Capital Management, LLC initiated holding in Ligand Pharmaceuticals Inc. The purchase prices were between $63.37 and $107.88, with an estimated average price of $91.15. The stock is now traded at around $94.10. The impact to a portfolio due to this purchase was 12.77%. The holding were 160,919 shares as of .

New Purchase: Stemline Therapeutics Inc (STML)

Stonepine Capital Management, LLC initiated holding in Stemline Therapeutics Inc. The purchase prices were between $3.41 and $10.79, with an estimated average price of $6.56. The stock is now traded at around $12.15. The impact to a portfolio due to this purchase was 4.68%. The holding were 886,632 shares as of .

New Purchase: Cidara Therapeutics Inc (CDTX)

Stonepine Capital Management, LLC initiated holding in Cidara Therapeutics Inc. The purchase prices were between $1.74 and $4.26, with an estimated average price of $3.02. The stock is now traded at around $2.92. The impact to a portfolio due to this purchase was 3.52%. The holding were 1,302,981 shares as of .

New Purchase: BioDelivery Sciences International Inc (BDSI)

Stonepine Capital Management, LLC initiated holding in BioDelivery Sciences International Inc. The purchase prices were between $3.06 and $6.32, with an estimated average price of $4.96. The stock is now traded at around $4.39. The impact to a portfolio due to this purchase was 3.12%. The holding were 755,000 shares as of .

New Purchase: DiaMedica Therapeutics Inc (F2KA)

Stonepine Capital Management, LLC initiated holding in DiaMedica Therapeutics Inc. The purchase prices were between $1.84 and $5.15, with an estimated average price of $3.71. The stock is now traded at around $3.70. The impact to a portfolio due to this purchase was 2.52%. The holding were 825,297 shares as of .

New Purchase: SeaSpine Holdings Corp (SPNE)

Stonepine Capital Management, LLC initiated holding in SeaSpine Holdings Corp. The purchase prices were between $6.08 and $16.42, with an estimated average price of $13.23. The stock is now traded at around $9.80. The impact to a portfolio due to this purchase was 2.26%. The holding were 253,131 shares as of .

Added: Catalyst Biosciences Inc (CBIO)

Stonepine Capital Management, LLC added to a holding in Catalyst Biosciences Inc by 231.68%. The purchase prices were between $3.5 and $8.51, with an estimated average price of $6.16. The stock is now traded at around $6.19. The impact to a portfolio due to this purchase was 3.39%. The holding were 1,019,196 shares as of .

Added: CTI BioPharma Corp (CTIC)

Stonepine Capital Management, LLC added to a holding in CTI BioPharma Corp by 71.26%. The purchase prices were between $0.69 and $1.58, with an estimated average price of $1.16. The stock is now traded at around $1.06. The impact to a portfolio due to this purchase was 2.68%. The holding were 6,430,637 shares as of .

Added: Chiasma Inc (CHMA)

Stonepine Capital Management, LLC added to a holding in Chiasma Inc by 305.17%. The purchase prices were between $2.98 and $5.18, with an estimated average price of $4.45. The stock is now traded at around $5.23. The impact to a portfolio due to this purchase was 2.23%. The holding were 744,134 shares as of .

Added: Evolus Inc (EOLS)

Stonepine Capital Management, LLC added to a holding in Evolus Inc by 108.40%. The purchase prices were between $3.53 and $12.21, with an estimated average price of $8.59. The stock is now traded at around $3.63. The impact to a portfolio due to this purchase was 1.94%. The holding were 822,960 shares as of .

Added: Interpace Biosciences Inc (PF42)

Stonepine Capital Management, LLC added to a holding in Interpace Biosciences Inc by 88.90%. The purchase prices were between $0.58 and $9.8, with an estimated average price of $6.33. The stock is now traded at around $5.05. The impact to a portfolio due to this purchase was 0.48%. The holding were 178,295 shares as of .

Sold Out: Novelion Therapeutics Inc (NVLNF)

Stonepine Capital Management, LLC sold out a holding in Novelion Therapeutics Inc. The sale prices were between $0.7 and $0.8, with an estimated average price of $0.73.

Sold Out: Aptevo Therapeutics Inc (APVO)

Stonepine Capital Management, LLC sold out a holding in Aptevo Therapeutics Inc. The sale prices were between $3.29 and $9.73, with an estimated average price of $6.81.

Sold Out: Strongbridge Biopharma PLC (SBBP)

Stonepine Capital Management, LLC sold out a holding in Strongbridge Biopharma PLC. The sale prices were between $1.57 and $3.51, with an estimated average price of $2.6.

Sold Out: SCYNEXIS Inc (SCYX)

Stonepine Capital Management, LLC sold out a holding in SCYNEXIS Inc. The sale prices were between $0.55 and $1.15, with an estimated average price of $0.9.

Sold Out: resTORbio Inc (TORC)

Stonepine Capital Management, LLC sold out a holding in resTORbio Inc. The sale prices were between $0.87 and $1.7, with an estimated average price of $1.33.

Sold Out: Acer Therapeutics Inc (ACER)

Stonepine Capital Management, LLC sold out a holding in Acer Therapeutics Inc. The sale prices were between $1.18 and $5.86, with an estimated average price of $3.7.



Here is the complete portfolio of Stonepine Capital Management, LLC. Also check out:

1. Stonepine Capital Management, LLC's Undervalued Stocks
2. Stonepine Capital Management, LLC's Top Growth Companies, and
3. Stonepine Capital Management, LLC's High Yield stocks
4. Stocks that Stonepine Capital Management, LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)